Hsbc Holdings PLC Buys Shares of 62,590 Elanco Animal Health Incorporated $ELAN

Hsbc Holdings PLC bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 62,590 shares of the company’s stock, valued at approximately $1,540,000.

Several other hedge funds have also recently modified their holdings of ELAN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Elanco Animal Health in the first quarter worth $2,065,000. Goldman Sachs Group Inc. boosted its position in shares of Elanco Animal Health by 104.5% during the first quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company’s stock valued at $50,268,000 after buying an additional 2,445,872 shares during the last quarter. Empowered Funds LLC boosted its position in shares of Elanco Animal Health by 35.2% during the first quarter. Empowered Funds LLC now owns 15,835 shares of the company’s stock valued at $166,000 after buying an additional 4,121 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company’s stock worth $18,830,000 after buying an additional 76,408 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Elanco Animal Health by 2,006.9% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 310,383 shares of the company’s stock worth $4,432,000 after buying an additional 295,651 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $24.01 on Tuesday. The firm has a market capitalization of $12.00 billion, a P/E ratio of -58.56, a PEG ratio of 1.44 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.05 and a quick ratio of 1.10. Elanco Animal Health Incorporated has a one year low of $17.11 and a one year high of $27.98. The business has a fifty day moving average of $24.62 and a 200 day moving average of $23.99.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.07. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.31 billion. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.Elanco Animal Health’s revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.12 EPS for the current year.

Insider Activity

In other Elanco Animal Health news, Director Paul Herendeen acquired 10,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The shares were bought at an average price of $23.68 per share, with a total value of $236,800.00. Following the completion of the acquisition, the director owned 111,687 shares in the company, valued at $2,644,748.16. This represents a 9.83% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence Erik Kurzius bought 40,000 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were acquired at an average price of $23.40 per share, with a total value of $936,000.00. Following the completion of the transaction, the director directly owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This trade represents a 26.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last ninety days, insiders have bought 63,198 shares of company stock worth $1,473,109. Company insiders own 1.14% of the company’s stock.

Analyst Ratings Changes

ELAN has been the topic of several research analyst reports. Wall Street Zen cut shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. TD Cowen boosted their price objective on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, June 18th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, August 20th. Finally, Citigroup increased their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.